XBiotech Announces First Patient Begins Novel Natrunix Therapy In Phase II Rheumatoid Arthritis Clinical Trial
Portfolio Pulse from Happy Mohamed
XBiotech Inc. has started treating the first patient in a phase II clinical study to evaluate Natrunix as a new treatment for Arthritis. The study is double-blind, placebo-controlled, and randomized. Natrunix is a monoclonal antibody that neutralizes the action of interleukin-1, a potent inflammation-causing substance. The study will enroll approximately 210 subjects into three different arms. All subjects will receive methotrexate and be randomized to receive either one of two doses of Natrunix or placebo.

August 08, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
XBiotech has started a phase II clinical trial for Natrunix, a potential new treatment for Arthritis. The success of this trial could significantly impact the company's future revenues and market position.
The initiation of the phase II clinical trial for Natrunix is a significant step for XBiotech. If the trial is successful, it could lead to the approval of a new treatment for Arthritis, a condition that affects millions of people. This could significantly increase the company's revenues and strengthen its position in the market. However, the outcome of the trial is uncertain and there are risks involved.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100